Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSGBR-0905)

H. R. Kim, K. H. Jung, S. A. Im, Y. H. Im, S. Y. Kang, Kyong Hwa Park, S. Lee, S. B. Kim, K. H. Lee, J. S. Ahn, S. I. Kim, J. H. Sohn

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: This phase II neoadjuvant trial evaluated bevacizumab-docetaxel and carboplatin in triple-negative breast cancer. Patients and methods: Women with hormone receptor- and human epidermal growth factor receptor 2 (HER2)- negative, stage II/III breast cancer received six cycles of 75 mg/m2 docetaxel, carboplatin (AUC = 5) and 15 mg/kg bevacizumab every 21 days. The primary end point was pathological complete response (pCR) in breasts and axillary lymph nodes (ALN). Results: Forty-five patients were recruited from the Korean Cancer Study Group. The median age was 45 (range 30-72) years. ALNs were positive in 80% of patients (n = 36) at diagnosis. Overall, 98% of patients (n = 44) completed therapy and underwent surgery. The pCR rate was 42% (n = 19); clinical response rate 96% (n = 43); complete 13% (n = 6); partial 82% (n = 37); stable disease 2% (n = 1). Breast-conserving surgery was undertaken in 78% of patients (n = 35). Most frequent grade 3/4 adverse events were neutropenia (84%, n = 38) and febrile neutropenia (9%, n = 4). One patient experienced delayed wound healing after surgery. Conclusions: Neoadjuvant bevacizumab, docetaxel and carboplatin resulted in an encouraging pCR rate and negligible wound healing problems after surgery.

Original languageEnglish
Pages (from-to)1485-1490
Number of pages6
JournalAnnals of Oncology
Volume24
Issue number6
DOIs
Publication statusPublished - 2013 Jun 1

Fingerprint

docetaxel
Triple Negative Breast Neoplasms
Neoadjuvant Therapy
Carboplatin
Wound Healing
Febrile Neutropenia
Segmental Mastectomy
Neutropenia
Area Under Curve
Bevacizumab
Breast
Lymph Nodes
Hormones
Breast Neoplasms

Keywords

  • Bevacizumab
  • Carboplatin
  • Docetaxel
  • Neoadjuvant chemotherapy
  • Pathological complete response
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSGBR-0905). / Kim, H. R.; Jung, K. H.; Im, S. A.; Im, Y. H.; Kang, S. Y.; Park, Kyong Hwa; Lee, S.; Kim, S. B.; Lee, K. H.; Ahn, J. S.; Kim, S. I.; Sohn, J. H.

In: Annals of Oncology, Vol. 24, No. 6, 01.06.2013, p. 1485-1490.

Research output: Contribution to journalArticle

Kim, H. R. ; Jung, K. H. ; Im, S. A. ; Im, Y. H. ; Kang, S. Y. ; Park, Kyong Hwa ; Lee, S. ; Kim, S. B. ; Lee, K. H. ; Ahn, J. S. ; Kim, S. I. ; Sohn, J. H. / Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSGBR-0905). In: Annals of Oncology. 2013 ; Vol. 24, No. 6. pp. 1485-1490.
@article{8caad9ac32254d499238e0fc5c39751b,
title = "Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSGBR-0905)",
abstract = "Background: This phase II neoadjuvant trial evaluated bevacizumab-docetaxel and carboplatin in triple-negative breast cancer. Patients and methods: Women with hormone receptor- and human epidermal growth factor receptor 2 (HER2)- negative, stage II/III breast cancer received six cycles of 75 mg/m2 docetaxel, carboplatin (AUC = 5) and 15 mg/kg bevacizumab every 21 days. The primary end point was pathological complete response (pCR) in breasts and axillary lymph nodes (ALN). Results: Forty-five patients were recruited from the Korean Cancer Study Group. The median age was 45 (range 30-72) years. ALNs were positive in 80{\%} of patients (n = 36) at diagnosis. Overall, 98{\%} of patients (n = 44) completed therapy and underwent surgery. The pCR rate was 42{\%} (n = 19); clinical response rate 96{\%} (n = 43); complete 13{\%} (n = 6); partial 82{\%} (n = 37); stable disease 2{\%} (n = 1). Breast-conserving surgery was undertaken in 78{\%} of patients (n = 35). Most frequent grade 3/4 adverse events were neutropenia (84{\%}, n = 38) and febrile neutropenia (9{\%}, n = 4). One patient experienced delayed wound healing after surgery. Conclusions: Neoadjuvant bevacizumab, docetaxel and carboplatin resulted in an encouraging pCR rate and negligible wound healing problems after surgery.",
keywords = "Bevacizumab, Carboplatin, Docetaxel, Neoadjuvant chemotherapy, Pathological complete response, Triple-negative breast cancer",
author = "Kim, {H. R.} and Jung, {K. H.} and Im, {S. A.} and Im, {Y. H.} and Kang, {S. Y.} and Park, {Kyong Hwa} and S. Lee and Kim, {S. B.} and Lee, {K. H.} and Ahn, {J. S.} and Kim, {S. I.} and Sohn, {J. H.}",
year = "2013",
month = "6",
day = "1",
doi = "10.1093/annonc/mds658",
language = "English",
volume = "24",
pages = "1485--1490",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSGBR-0905)

AU - Kim, H. R.

AU - Jung, K. H.

AU - Im, S. A.

AU - Im, Y. H.

AU - Kang, S. Y.

AU - Park, Kyong Hwa

AU - Lee, S.

AU - Kim, S. B.

AU - Lee, K. H.

AU - Ahn, J. S.

AU - Kim, S. I.

AU - Sohn, J. H.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Background: This phase II neoadjuvant trial evaluated bevacizumab-docetaxel and carboplatin in triple-negative breast cancer. Patients and methods: Women with hormone receptor- and human epidermal growth factor receptor 2 (HER2)- negative, stage II/III breast cancer received six cycles of 75 mg/m2 docetaxel, carboplatin (AUC = 5) and 15 mg/kg bevacizumab every 21 days. The primary end point was pathological complete response (pCR) in breasts and axillary lymph nodes (ALN). Results: Forty-five patients were recruited from the Korean Cancer Study Group. The median age was 45 (range 30-72) years. ALNs were positive in 80% of patients (n = 36) at diagnosis. Overall, 98% of patients (n = 44) completed therapy and underwent surgery. The pCR rate was 42% (n = 19); clinical response rate 96% (n = 43); complete 13% (n = 6); partial 82% (n = 37); stable disease 2% (n = 1). Breast-conserving surgery was undertaken in 78% of patients (n = 35). Most frequent grade 3/4 adverse events were neutropenia (84%, n = 38) and febrile neutropenia (9%, n = 4). One patient experienced delayed wound healing after surgery. Conclusions: Neoadjuvant bevacizumab, docetaxel and carboplatin resulted in an encouraging pCR rate and negligible wound healing problems after surgery.

AB - Background: This phase II neoadjuvant trial evaluated bevacizumab-docetaxel and carboplatin in triple-negative breast cancer. Patients and methods: Women with hormone receptor- and human epidermal growth factor receptor 2 (HER2)- negative, stage II/III breast cancer received six cycles of 75 mg/m2 docetaxel, carboplatin (AUC = 5) and 15 mg/kg bevacizumab every 21 days. The primary end point was pathological complete response (pCR) in breasts and axillary lymph nodes (ALN). Results: Forty-five patients were recruited from the Korean Cancer Study Group. The median age was 45 (range 30-72) years. ALNs were positive in 80% of patients (n = 36) at diagnosis. Overall, 98% of patients (n = 44) completed therapy and underwent surgery. The pCR rate was 42% (n = 19); clinical response rate 96% (n = 43); complete 13% (n = 6); partial 82% (n = 37); stable disease 2% (n = 1). Breast-conserving surgery was undertaken in 78% of patients (n = 35). Most frequent grade 3/4 adverse events were neutropenia (84%, n = 38) and febrile neutropenia (9%, n = 4). One patient experienced delayed wound healing after surgery. Conclusions: Neoadjuvant bevacizumab, docetaxel and carboplatin resulted in an encouraging pCR rate and negligible wound healing problems after surgery.

KW - Bevacizumab

KW - Carboplatin

KW - Docetaxel

KW - Neoadjuvant chemotherapy

KW - Pathological complete response

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84878449611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878449611&partnerID=8YFLogxK

U2 - 10.1093/annonc/mds658

DO - 10.1093/annonc/mds658

M3 - Article

VL - 24

SP - 1485

EP - 1490

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

ER -